Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
Yamaguchi T, Hozumi Y, Sagara Y, Takahashi M, Yoneyama K, Fujisawa T, Osumi S, Akabane H, Nishimura R, Mieno MN, Mukai H. Yamaguchi T, et al. Among authors: takahashi m. Surg Oncol. 2021 Mar;36:51-55. doi: 10.1016/j.suronc.2020.11.008. Epub 2020 Nov 20. Surg Oncol. 2021. PMID: 33310293 Clinical Trial.
Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Miyoshi Y, et al. Among authors: takahashi m. J Cancer Res Clin Oncol. 2008 May;134(5):561-7. doi: 10.1007/s00432-007-0319-5. Epub 2007 Oct 16. J Cancer Res Clin Oncol. 2008. PMID: 17938960
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Takahashi S, Iwase T, Kohno N, Ishikawa T, Taguchi T, Takahashi M, Horiguchi J, Nakamura S, Hozumi Y, Fukunaga M, Noguchi S. Takahashi S, et al. Among authors: takahashi m. Breast Cancer Res Treat. 2012 Jun;133(2):685-93. doi: 10.1007/s10549-012-1973-0. Epub 2012 Feb 4. Breast Cancer Res Treat. 2012. PMID: 22307266 Clinical Trial.
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, Liu Z, Nishimura R, Osako T, Okido M, Shimada K, Takahashi M, Chu P, Yuan YC, Chen S. Kubo M, et al. Among authors: takahashi m. Breast Cancer Res Treat. 2013 Jan;137(1):93-107. doi: 10.1007/s10549-012-2332-x. Epub 2012 Nov 18. Breast Cancer Res Treat. 2013. PMID: 23160924 Free PMC article.
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer.
Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S; Japanese Breast Cancer Society. Mukai H, et al. Among authors: takahashi m. Breast Cancer. 2015 Jan;22(1):5-15. doi: 10.1007/s12282-014-0563-x. Epub 2014 Sep 9. Breast Cancer. 2015. PMID: 25200171 No abstract available.
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M. Yamshiro H, et al. Among authors: takahashi m. Int J Clin Oncol. 2015 Aug;20(4):709-22. doi: 10.1007/s10147-015-0785-8. Epub 2015 Feb 10. Int J Clin Oncol. 2015. PMID: 25666483
Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients.
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M. Yamshiro H, et al. Among authors: takahashi m. Int J Clin Oncol. 2015 Aug;20(4):723-4. doi: 10.1007/s10147-015-0814-7. Int J Clin Oncol. 2015. PMID: 25772578 No abstract available.
Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, Osako T, Takahashi M, Endo Y, Hosoda M, Ishida N, Horii R, Yamazaki K, Miyoshi Y, Yasojima H, Tomioka N; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Yamashita H, et al. Among authors: takahashi m. Breast Cancer. 2016 Nov;23(6):830-843. doi: 10.1007/s12282-015-0649-0. Epub 2015 Oct 14. Breast Cancer. 2016. PMID: 26467036 Free article.
15,233 results
You have reached the last available page of results. Please see the User Guide for more information.